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Identification of a novel ubiquitin-conjugating enzyme involved
in mitotic cyclin degradation
Hongtao Yu, Randall W. King, Jan-Michael Peters and Marc W. Kirschner
Background: The destruction of cyclin B is required for exit from mitosis, and is
mediated by the ubiquitin pathway. Recently, a 20S complex, termed the
anaphase-promoting complex (APC) or the cyclosome, has been genetically and
biochemically identified as the cyclin-specific ubiquitin ligase (E3). In addition, a
ubiquitin-conjugating enzyme (E2), UBC4, was shown to be involved in cyclin
ubiquitination in Xenopus egg extracts. Another E2 activity, designated UBCx,
can independently support cyclin ubiquitination in Xenopus. A similar activity
(E2-C) has also been observed in clams. However, the molecular identity of
Xenopus UBCx or clam E2-C has not been established.
Results: We have purified and cloned Xenopus UBCx. Sequence comparisons
with known E2s reveal that UBCx is a novel ubiquitin-conjugating enzyme.
Purified recombinant UBCx is sufficient to complement purified APC and E1 in
destruction box-dependent cyclin ubiquitination. UBCx and UBC4 are active in a
similar concentration range and with similar kinetics. At saturating enzyme
concentrations, UBCx converts twice as much substrate into ubiquitin
conjugates, but generates conjugates of lower molecular mass than UBC4.
Conclusions: UBCx is a novel ubiquitin-conjugating enzyme involved in cyclin
ubiquitination in Xenopus. Like UBC4, ubiquitination catalyzed by UBCx is
dependent on both the destruction box and the APC, suggesting that these E2s
function through a similar mechanism. However, as the patterns of conjugates
generated by these E2s are distinct, these enzymes may play different roles in
promoting cyclin proteolysis in mitosis. 
Background
The early Xenopus embryonic cell cycle is driven by fluc-
tuations in the level of cyclin B, the activating subunit of
the protein kinase p34cdc2 [1,2]. While cyclin B is continu-
ously synthesized, its level is controlled by the periodic
activation of a highly substrate-specific proteolytic system:
cyclin B is stable during interphase, but is rapidly
degraded late in mitosis as cells undergo anaphase. Over-
expression of nondegradable mutants of cyclin B arrests
cells in telophase with sustained p34cdc2 kinase activity
[3–8], indicating that cyclin proteolysis is necessary for
kinase inactivation and subsequent exit from mitosis. It is
therefore the regulated activation and inactivation of
cyclin proteolysis that drives the early embryonic cell
cycle [9].
Cyclin B is degraded by the ubiquitin–proteasome
pathway [10,11], in which the covalent attachment of
ubiquitin to cyclin B targets the protein for degradation by
the 26S proteasome [12,13]. The ubiquitination of cyclin
B requires the presence of a specific degradation signal in
cyclin called the destruction box (D box) [10]. Several
components required for cyclin ubiquitination have been
identified recently by biochemical and genetic approaches
([14–18]; reviewed in [19–22]). In addition to the ubiqui-
tin-activating enzyme E1, cyclin ubiquitination involves at
least two distinct E2 enzymes, or ubiquitin-conjugating
enzymes, neither of which is cell-cycle regulated [14,16].
The mitotic specificity of cyclin ubiquitination occurs
through activation of a cyclin-ubiquitin ligase or E3 activ-
ity that is associated with a large protein complex, called
the cyclosome in clams [17] or the anaphase-promoting
complex (APC) in vertebrates and yeast [16]. APC puri-
fied from Xenopus contains at least eight distinct proteins
[16], including homologs of budding yeast CDC16 and
CDC27, which are essential for the onset of anaphase in
both fungi and mammalian cells [15,18].
Previous studies have identified several E2 activities that
can cooperate with the cell-cycle regulated E3 component
to ubiquitinate cyclin B. In clams, a single E2 activity
called E2-C can complement partially purified cyclosome
preparations to ubiquitinate cyclin B [14,17]. In Xenopus,
two distinct E2 activities can cooperate with APC to ubiq-
uitinate cyclin B in a D box-dependent manner. One of
these has been identified as a homolog of budding yeast
Address: Department of Cell Biology, Harvard
Medical School, 240 Longwood Avenue, Boston,
Massachusetts 02115, USA.
Correspondence to: Marc W. Kirschner
E-mail address: MKirschn.warren.med.harvard.edu
Received: 24 January 1996
Revised: 23 February 1996
Accepted: 26 February 1996
Current Biology 1996, Vol 6 No 4:455–466
© Current Biology Ltd ISSN 0960-9822
Research Paper 455
UBC4 [16]. This E2 also participates in the degradation of
several other classes of proteins, including the MATa2
repressor [23], the tumor suppressor p53 [24,25], and mis-
folded or damaged proteins [26]. The second E2 activity
in Xenopus, called UBCx, has not been molecularly charac-
terized [16]. The chromatographic characteristics of UBCx
indicate that this protein is not a Xenopus homolog of
UBC9, a protein implicated in cyclin proteolysis in yeast
[27]. It remains possible, however, that UBCx is the
Xenopus homolog of clam E2-C. 
To identify UBCx, and to understand the mechanism by
which UBC4 and UBCx cooperate with APC to ubiquiti-
nate cyclin B, we have purified and cloned UBCx from
Xenopus. UBCx is a novel ubiquitin-conjugating enzyme,
most closely related to yeast and human UBC2. Rec-
ombinant UBCx can function with purified APC to
ubiquitinate cyclin B in a D box-dependent manner.
Dose-response experiments indicate that UBC4 and
UBCx are active over a similar range of concentrations.
At saturating enzyme concentrations, UBCx converts a
greater proportion of substrate into ubiquitin conjugates.
However, the conjugates generated by UBCx are of lower
molecular mass than those generated with UBC4. These
data suggest that although UBCx and UBC4 function
through a similar APC-dependent mechanism, the
pattern of conjugates produced is influenced by the
nature of the E2, indicating that these E2s may play dis-
tinct roles in cyclin degradation.
Results
Purification and molecular cloning of UBCx
We have shown previously that components of the mitotic
cyclin ubiquitination machinery in Xenopus egg extracts
can be separated into cell-cycle regulated and unregulated
fractions by Resource Q chromatography [16]. The Q-
binding fraction, Q2, contains the ubiquitin-activating
enzyme (E1) and the mitotically-regulated 20S complex
(APC) that possesses a cyclin-specific ubiquitin ligase (E3)
activity. The Q flowthrough fraction, Q1, contains two dis-
tinct E2s that each supports cyclin ubiquitination in con-
junction with fraction Q2. One of the two UBCs was
previously shown to be a homolog of yeast UBC4 [16]. To
complete our identification of the components involved in
cyclin ubiquitination, we set out to purify the other E2
enzyme, UBCx.
Because the activity of UBCx is not cell cycle-regulated,
we used interphase extracts as our starting material for the
purification of this enzyme. Each purification step was
monitored by testing the column fractions for their ability
to complement a mitotic Q2 fraction to ubiquitinate an
iodinated amino-terminal fragment of sea urchin cyclin B
(residues 13–110) in the presence of ATP and ubiquitin. It
has been shown that this amino-terminal fragment of
cyclin B is degraded in a cell cycle-dependent way [8],
although this peptide is not able to bind to p34cdc2 [28].
The column fractions were also analyzed by E2 thioester
assays with purified recombinant E1 and radiolabeled
ubiquitin. Although the ubiquitination assay was more
sensitive, the thioester assay was more linear with respect
to the concentration of UBCx.
Our purification scheme is shown in Figure 1a. We pre-
pared fraction Q1 from 220 ml of concentrated Xenopus egg
extract (7 g protein). Fraction Q1 was applied to a phenyl
sepharose column, from which UBCx eluted at 25 mM
ammonium sulfate, much later than UBC4. Active frac-
tions were applied to Hi-Trap Q at pH 9.0. Activity eluted
at 150 mM KCl, and the peak fractions were subsequently
separated by gel filtration chromatography. Activity eluted
with an apparent molecular mass of approximately 30 kDa,
as observed previously [16].
A single ubiquitin thioester of 29 kDa cofractionated with
UBCx activity (Fig. 1b,c), suggesting that the activity was
due to a single E2 enzyme with a relative molecular mass
of 21 kDa (ubiquitin itself contributes a mass of 8.6 kDa to
the thioester). A 21 kDa polypeptide cofractionated with
both the ubiquitination and thioester-forming activities
(Fig. 1d), suggesting that this band represented UBCx. 
This protein was analyzed by amino-acid sequencing of
two peptides generated by digestion with Lys-C (Fig. 2),
yielding sequences of 18 residues (peptide A) and 10
residues (peptide B). These peptides did not match any
known proteins in the database. However, searches of the
expressed sequence tag (EST) database identified three
overlapping human ESTs (R80990, R95056, T86566) that
encode amino-acid sequences with 83 % identity to
peptide A and 80 % identity to peptide B. These three
ESTs together encode a predicted protein that is similar
in sequence to ubiquitin-conjugating enzymes. Based on
the EST sequences, we isolated a cDNA clone
(H.s.UBCx-1) from a human testis library that contains an
open reading frame of 179 amino acids, corresponding to a
20 kDa protein. 
We subsequently cloned the Xenopus UBCx cDNA. Based
on the human sequence, we oriented peptides A and B
and designed the corresponding degenerate oligonu-
cleotides. These were used as primers in polymerase chain
reactions (PCRs) to test pools of a subdivided Xenopus
cDNA library [29] for the presence of a Xenopus UBCx
clone. Positive pools were then subdivided until single
clones were obtained. One clone, designated X.l.UBCx-1,
contained a cDNA insert of 1.0 kb and encoded a protein
with a predicted mass of 20 kDa (Fig. 2). A stop codon
immediately preceded the initiating methionine, suggest-
ing that this clone contained the complete open reading
frame. The sequences of peptides A and B matched the
amino-acid sequence encoded by the X.l.UBCx-1 cDNA
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(Fig. 2), suggesting that the cDNA encodes the Xenopus
UBCx protein.
We expressed the X.l.UBCx-1 cDNA in Escherichia coli
and purified the recombinant protein to homogeneity,
using a purification protocol similar to that used to purify
UBCx from Xenopus extracts (see Materials and methods).
The recombinant 21 kDa protein formed a ubiquitin
thioester that comigrated on SDS-PAGE with that formed
by UBCx from extracts (Fig. 4b). The recombinant
protein could also complement either fraction Q2 or APC
immunoprecipitated with CDC27 antibodies (Fig. 4c).
The patterns of cyclin–ubiquitin conjugates formed by
the recombinant protein and by UBCx purified from
Xenopus egg extracts were indistinguishable. Similar
results were obtained with bacterially expressed human
UBCx (data not shown). In the presence of mitotic APC,
both recombinant proteins were also active in ubiquitinat-
ing amino-terminal fragments (residues 1–102) of the
Xenopus cyclins B1 and B2 when used as substrates (data
not shown). Taken together, these results demonstrate
that the isolated cDNAs encode the human and Xenopus
versions of the UBCx protein. As the UBCx protein has a
molecular mass of 21 kDa but elutes from gel filtration
columns with an apparent molecular mass of approxi-
mately 30 kDa, it is presently unclear whether the native
enzyme is a monomer or a dimer. 
Sequence comparison between UBCx and known E2s
showed that UBCx is a novel member of the family of
ubiquitin-conjugating enzymes. The highest similarity
was observed between UBCx and UBC2 from either yeast
or human (approximately 40 % identity at the amino-acid
level; Fig. 3). However, previous work has shown that
recombinant purified human UBC2 is unable to support
cyclin ubiquitination [16], indicating that the two enzymes
are functionally distinct.
Based on the sequence homology with other E2s, the
cysteine at position 114 of UBCx is likely to be the active-
site residue that forms a thioester with ubiquitin. UBCx
contains a conserved 16 kDa domain that is characteristic
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Figure 1
Purification of UBCx from Xenopus egg
extracts. (a) Purification scheme. (b) Cyclin
ubiquitination assay performed on the gel
filtration fractions. The reaction contained the
column fractions, an equal volume of mitotic
fraction Q2, ATP, ubiquitin, and 125I-labeled
cyclin amino-terminal fragment. (c) E2
thioester assay performed on the same
fractions. Each fraction was assayed by
addition of recombinant E1 and 125I-ubiquitin
in the presence of ATP. The band of the
UBCx–ubiquitin (UBCx–Ub) thioester is
labeled. (d) Fractions were separated on
SDS-PAGE and silver-stained. The UBCx
band is labeled. 
of E2 enzymes [30]; in this region, UBCx shares relatively
low amino-acid identities with the known yeast E2s,
ranging from 17–43 %. In addition to the E2 domain,
UBCx also contains short amino- and carboxy-terminal
extensions. Although Xenopus and human UBCx share
90 % identity in the 16 kDa conserved region, the amino-
and carboxy-terminal extensions are only 65 % and 52 %
identical, respectively (71 % and 64 % similarities,
respectively).
To compare the enzymatic properties of Xenopus UBCx and
UBC4, we also isolated a cDNA encoding Xenopus UBC4,
which is highly related to the different isoforms of human
UBC4 (99 % amino-acid identity to UBC-H5 [24], 100 %
identity to UBC-H5b and 97 % identity to UBC-H5c [31]).
We also expressed Xenopus UBC4 in bacteria and purified
the recombinant protein. As shown in Figure 4a, the
recombinant proteins used in the subsequent experiments,
such as E1, UBC4, and UBCx, were relatively pure. When
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Figure 2
The cDNA and amino-acid sequences of
Xenopus UBCx. Two peptides (A and B) that
match the amino-acid sequencing data are
boxed. The putative active site cysteine
(Cys114) is underlined and the stop codon is
indicated by an asterisk.
Figure 3
UBCx is a novel member of the E2 family. (a) Schematic drawing of
the sequence alignment among Xenopus UBCx and representative
yeast or human UBCs. The sequence identity (%) is shown. The
16 kDa conserved E2 domain is shaded and the active site is indicated
by an asterisk. (b) Phylogenetic tree of the UBCs. Abbreviations: H.s.,
Human; S.c., Saccharomyces cerevisiae; X.l., Xenopus laevis.
incubated in the presence of E1 and ATP for 20 minutes,
about 60 % of the recombinant Xenopus UBC4 and UBCx
proteins formed thioesters with ubiquitin. 
Cyclin ubiquitination mediated by UBCx or UBC4 is 
D box-dependent
Mitotic cyclins contain a short sequence motif called the
destruction box (D box) that serves as the major prote-
olytic signal. In the case of sea urchin cyclin B, the D box
consists of residues 42-RAALGNISN-50 [10]. We tested
whether reactions catalyzed by recombinant UBC4 or
UBCx were D box-dependent. Four different substrates
were used in the reactions: an amino-terminal fragment of
sea urchin cyclin B (residues 13–110) [8], the same frag-
ment with a mutated D box (R42A, A44R, designated
AARL) [8], a shorter cyclin B fragment (residues 13–66)
fused to protein A [10], or a D box deletion mutant of this
substrate (DDB) (R.W.K. and M.W.K., unpublished
results). Ubiquitin conjugates were observed in the pres-
ence of the wild-type substrates in both reconstituted
systems (Q2 and APC; Fig. 5). Point mutation of the D
box decreased, but did not eliminate ubiquitination cat-
alyzed by either enzyme, as we had observed previously
with UBC4 [16]. In contrast, the DDB substrate yielded
no conjugates (Fig. 5). These observations suggest that
recognition of cyclins by APC requires the intact D box in
the reactions reconstituted with either UBC4 or UBCx. 
Ubiquitination of the AARL mutant was more strongly
suppressed in the presence of fraction Q2 than in those
reconstituted with immunopurified APC. This difference
could be due to the existence of additional specificity
factors in fraction Q2. Alternatively, this may reflect the
physical differences of the reaction conditions: the reac-
tion catalyzed by immunopurified APC occurs at the inter-
face between Affiprep beads and components in solution,
whereas reactions using fraction Q2 occur entirely in a
soluble phase.
UBCx favors the formation of cyclin conjugates with short
ubiquitin chains
To compare the activities of Xenopus UBCx and UBC4 in
the reconstituted reactions, we analyzed the effect of
varying the concentration of the two E2 enzymes in the
presence of fixed amounts of fraction Q2 or immunopuri-
fied APC. The amounts of conjugates formed in these
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Figure 4
Recombinant Xenopus UBCx forms a ubiquitin thioester of the same
size as the purified protein and catalyzes the formation of cyclin-
ubiquitin conjugates with similar patterns. (a) Recombinant proteins
used in subsequent experiments were analyzed by SDS-PAGE (silver-
stained). Recombinant UBC4 (200 µg ml–1) or UBCx (200 µg ml–1) was
also incubated with E1 (200 µg ml–1) and ubiquitin (Ub) (2 mg ml–1) in
the presence or absence of ATP for 20 min, and 5 µl of each reaction
was analyzed by SDS-PAGE and silver-staining. The positions of
UBCx–Ub, UBC4–Ub, and E1–Ub thioesters are indicated. (b) E2
thioester assay with either recombinant (50 µg ml–1) or purified UBCx.
Fraction 15 of the Superdex-75 gel filtration column was used as the
source of partially purified UBCx. (c) Ubiquitination assay with either
recombinant (50 µg ml–1) or purified UBCx in the presence of either a
mitotic Q2 fraction or the immunopurified APC (CDC27-IP). 
reactions reached plateau levels when 20 µg ml–1 of UBCx
or UBC4 was used in the Q2 reaction and 10 µg ml–1 of
either enzyme was used in the reactions containing
purified APC (Fig. 6). At saturation, UBCx converted
about 2.5 fold more substrate into ubiquitin conjugates
than UBC4 when fraction Q2 was used, and 1.3 fold more
when immunopurified APC was used. 
We observed a significant difference in the patterns of
cyclin–ubiquitin conjugates formed by these two enzymes
at all concentrations (Fig. 6). UBCx favored the formation
of low molecular mass conjugates while UBC4 supported
the formation of conjugates with higher molecular mass,
suggesting that UBC4 is more processive and generates
longer ubiquitin chains. For both E2s, the reactions cat-
alyzed by purified APC produced conjugates of lower mass
compared to those generated in the Q2 reactions. Presently,
we do not know whether this difference results from the
physical differences in reaction conditions or is influenced
by the presence of additional factors in the Q2 fraction.
When we analyzed cyclin ubiquitination reactions that con-
tained both UBCx and UBC4, we did not see synergy
between the two activities. Instead, the amount of
substrate converted into ubiquitin conjugates increased
additively over a wide range of E2 concentrations
(0.5–8 mg ml–1 for UBCx; 1–16 mg ml–1 for UBC4), either in
the presence of fraction Q2 or immunopurified APC (Fig. 7
and data not shown). The profile of the cyclin–ubiquitin
conjugates generated in the presence of both UBC4 and
UBCx closely resembled the sum of the individual profiles
obtained with either UBC4 or UBCx (Fig. 7).
The cyclin substrate used in our studies, the sea urchin
cyclin B fragment (residues 13–110), contains ten lysines
that can potentially form isopeptide bonds with ubiquitin.
We have found that cyclin amino-terminal fragments are
ubiquitinated at multiple sites in crude extracts (R.W.K.
and M.W.K., unpublished results). To examine whether
the cyclin–ubiquitin conjugates generated by UBCx origi-
nate from mono-ubiquitination on multiple sites, we
added methylated ubiquitin, a chemically modified mol-
ecule that cannot generate polyubiquitin chains, to our
reconstituted reactions (Fig. 8). Four or five major bands
were observed for either the UBCx- or UBC4-catalyzed
reactions. Because only one molecule of methylated ubiq-
uitin can be attached at each site, the number of bands
observed in these experiments corresponds to the number
of lysine residues on the substrate that form isopeptide
bonds with ubiquitin. Therefore, both UBCx and UBC4
can apparently initiate cyclin ubiquitination at multiple
sites. Furthermore, the number of bands did not increase
when both UBCx and UBC4 were added in the reaction,
suggesting that the two E2s catalyze the attachment of
ubiquitin molecules to the same set of lysine residues. In
the reactions containing UBCx and immunopurified APC,
we observed only a small difference between the patterns
of conjugates that were formed in the presence of either
ubiquitin or methylated ubiquitin (Fig. 8). This suggests
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Figure 5
The reactions reconstituted with either UBCx or UBC4 in the presence
of Q2 or CDC27-IP are destruction box-dependent. (a) Ubiquitination
assays performed with UBC4 (50 µg ml–1) or UBCx (25 µg ml–1) in the
presence of Q2 or CDC27-IP. The 125I substrates used in the
reactions are either a wild-type amino-terminal cyclin fragment
(residues 13–110) (WT) or a fragment that contains D box mutations
R42A and A44R (AARL). (b) Same as (a), except that a wild-type
cyclin–protein A fusion (WT) and a D box deletion mutant of the
cyclin–protein A fusion (DDB) were used as substrates in the assays.
The band indicated by an arrow represents a contaminant protein.
that UBCx predominantly mono-ubiquitinates cyclin at
multiple sites under these conditions.
UBCx and UBC4 catalyze cyclin B ubiquitination with
similar kinetics
Cyclin ubiquitination and degradation are rapid processes
in vivo and also in mitotic extracts of Xenopus eggs, in
which the sea urchin cyclin fragment 13–110 is degraded
with a half-life of 5 minutes [16]. Ubiquitin conjugates of
this substrate were observed within 1–2 minutes and
reached steady state levels within 5 minutes [16]. We
obtained similar results when we measured the rate of
ubiquitination reactions containing fraction Q2 and either
UBCx or UBC4. Conjugates were formed within 1 minute
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Figure 7
UBCx and UBC4 function in an additive fashion. (a) The profile of the
cyclin–Ub conjugates formed by UBCx (4 mg ml–1). The intensity of
conjugates (PSL) is plotted against the distance (mm) between the
conjugates and the free substrate on SDS-PAGE. To show the profile
of the high mass conjugates, two different scales are used for the two
halves of the plot, as indicated by the dashed line. (b) The profile of
the cyclin–Ub conjugates formed by UBC4 (8 mg ml–1). (c)
Comparison of the profile of the cyclin–Ub conjugates in the presence
of both UBCx (4 mg ml–1) and UBC4 (8 mg ml–1) (solid line) with the
sum of profiles (dashed line) shown in (a,b).
Figure 6
Dose-response experiments measuring the
ability of UBCx or UBC4 to complement a
mitotic Q2 fraction or CDC27-IP. (a) Assays
reconstituted with UBCx (0–100 µg ml–1) or
UBC4 (0–100 µg ml–1) in the presence of
Q2. (b) Assays reconstituted with UBCx
(0–50 µg ml–1) or UBC4 (0–50 µg ml–1) in the
presence of CDC27-IP. (c,d) Quantitation of
assays shown in (a) and (b), respectively. The
amount of cyclin–ubiquitin conjugates was
measured using a Fuji phosphorimager and is
indicated in arbitrary units.
and levels plateaued between 5 and 10 minutes (Fig. 9a).
Identical values were obtained when each E2 was tested
at two different concentrations (5 and 20 µg ml–1 for
UBCx; 10 and 40 µg ml–1 for UBC4). The reactions con-
taining immunoprecipitated APC were about two fold
slower, with plateaus reached at approximately 20 minutes
(Fig. 9b). Compared to UBC4, UBCx converted more sub-
strate into ubiquitin conjugates at a given time. Because
the average mass of the UBC4-catalyzed conjugates was
higher than that of the UBCx-generated ones, the differ-
ence between the two E2s became less dramatic when we
plotted the amount of ubiquitin incorporated into cyclin
conjugates (data not shown).
UBC4 and UBCx catalyze cyclin ubiquitination with
similar kinetics in reactions containing either Q2 or puri-
fied APC. We noticed, however, that the amount of conju-
gates formed by UBC4 in the presence of fraction Q2
decreased after reaching a maximum at 10 minutes (Fig.
9a). This was mostly due to a decrease in the amount of
conjugates containing more than four ubiquitin molecules
(Fig. 9d). In contrast, the total amount of conjugates did
not decrease in any of the other reactions. The disappear-
ance of high molecular mass conjugates formed by UBC4 is
probably due to degradation catalyzed by 26S proteasomes,
which we know are present in fraction Q2 (our unpub-
lished results). Proteasomes preferentially degrade conju-
gates with long ubiquitin chains [32,33], which may explain
why the amount of conjugates formed by UBCx was not
affected by the presence of fraction Q2. It is also conceiv-
able that fraction Q2 contains deubiquitinating enzymes
that preferentially remove longer ubiquitin chains.
Discussion
Exit from mitosis requires the activation of a proteolytic
system that degrades cyclin B, the regulatory subunit of
the mitotic kinase p34cdc2 [9,20]. This destruction system is
also thought to initiate anaphase by ubiquitinating and
degrading a hypothetical inhibitor of chromosome segrega-
tion [7,8]. We have previously identified several compo-
nents of this degradation system in mitotic Xenopus egg
extracts: a 20S complex that contains a cell cycle-regulated
ubiquitin ligase (E3) activity, termed the anaphase-pro-
moting complex (APC), and two ubiquitin-conjugating
(E2) enzymes, one of which was identified as a homolog of
UBC4 [16]. To complete our identification of the compo-
nents required for cyclin ubiquitination, we have now puri-
fied the second E2 activity, called UBCx, from Xenopus
eggs, isolated the corresponding human and Xenopus
cDNA clones, and characterized its enzymatic properties.
UBCx is a novel E2 enzyme involved in cyclin
ubiquitination
Based on our sequence analysis, UBCx appears to be a
novel member of the family of ubiquitin-conjugating
enzymes. UBCx is a 21 kDa protein that contains the
highly conserved 16 kDa ‘E2 domain’ found in all
members of this family [30] and short amino- and carboxy-
terminal extensions. Comparison of the human and
Xenopus UBCx sequences shows that these extensions are
less conserved than the central E2 domain, suggesting that
the extensions may not be essential for the enzymatic
activity of UBCx.
Several other E2 enzymes have previously been reported
to play a role in mitotic cyclin ubiquitination. In budding
yeast, UBC9 has been implicated in destruction of Clb2
and Clb5 [27]. A Xenopus homolog of UBC9 has been
identified but this enzyme did not cofractionate with the
cyclin ubiquitinating activities found in mitotic egg
extracts [16]. Our sequence analysis has now confirmed
that UBC9 and UBCx are distinct enzymes. Recently,
E2-C, an enzyme that can support mitotic cyclin ubiquiti-
nation in clam extracts, has been cloned [34]. E2-C shares
65 % amino-acid sequence identity with Xenopus UBCx.
This suggests that this E2 is present in a broad range of
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Figure 8
UBCx and UBC4 catalyze cyclin ubiquitination at the same set of
lysine residues. As indicated, assays were performed with the addition
of ubiquitin (Ub) or methylated ubiquitin (MeUb). As indicated, these
reactions also contained UBC4 (50 µg ml–1), UBCx (20 µg ml–1), or
both E2s (25 µg ml–1 of UBC4 and 10 µg ml–1 of UBCx) in the
presence of CDC27-IP.
metazoan organisms from clam to human. A cDNA identi-
cal to human UBCx, termed human E2-C, has also been
isolated by Ruderman and coworkers (F. Townsley and J.
Ruderman, personal communication). To our knowledge,
nine other human ubiquitin-conjugating enzymes have
been cloned to date ([35,36]; S. Jentsch, personal commu-
nication). We decided in agreement with Ruderman and
colleagues to refer to the human homolog of UBCx and
E2-C as UBC-H10.
In Xenopus extracts, cyclin ubiquitination can be cat-
alyzed independently by UBCx or UBC4 [16]. In
budding yeast, synthetic lethality has been observed
between UBC4 and CDC23, a putative subunit of APC,
suggesting that these proteins function in the same
pathway [15]. Yeast cells from which the genes encoding
UBC4 and its close relative UBC5 have been deleted
grow extremely slowly but do not show a specific cell-
cycle arrest [26]. This may be due to the pleiotropic
effects of the mutation or to functional redundancy
among E2s involved in cyclin ubiquitination. It will
therefore be interesting to identify orthologs of UBCx in
yeast and to analyze their potential function in cyclin
degradation.
UBCx and UBC4 differ in their ability to promote
polyubiquitination of cyclin B
In ubiquitination reactions reconstituted with recombi-
nant E2 enzymes, we observed that UBCx converts the
cyclin substrate only into low molecular mass ubiquitin
conjugates, whereas UBC4 catalyzes the formation of
higher mass conjugates, suggesting that UBC4 is more
processive. The cyclin–ubiquitin conjugates formed by
UBC4 may be more prone to degradation by 26S protea-
somes or to disassembly by isopeptidases than those pro-
duced by UBCx. This is consistent with the previous
observation that 26S proteasomes preferentially degrade
conjugates with long ubiquitin chains [32,33]. Although
UBCx appears to be less processive than UBC4, UBCx is
active at lower concentrations and converts a greater pro-
portion of the substrate into ubiquitin conjugates.
It is presently unclear why multiple E2s are involved in
the ubiquitination of cyclin B. One intriguing possibility is
that UBCx and UBC4 play distinct roles in the cyclin
ubiquitination reaction. Based on our observations, it is
conceivable that the primary function of UBCx may be to
initiate ubiquitination by attaching one or two ubiquitin
monomers per lysine residue of the substrate. UBC4 could
then elongate these short ubiquitin chains to produce con-
jugates that could be more efficiently recognized by the
26S proteasome. However, we did not observe synergy
between UBC4 and UBCx over a wide concentration
range in our reconstituted reactions, but this does not rule
out the possibility that both E2s cooperate in assembling
the polyubiquitin chains on cyclin B under physiological
conditions. It is difficult to assess the individual contribu-
tions of UBCx and UBC4 under such conditions, as the
patterns of the cyclin–ubiquitin conjugates observed in
crude extracts are complicated by competing isopeptidase
and degradation reactions. Another possibility is that the
physiological role of UBCx is to modify the substrate by
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Figure 9
Kinetics of the reconstituted cyclin
ubiquitination reactions. (a,b) Quantitation of
cyclin ubiquitination activity reconstituted with
UBC4 (10 or 40 µg ml–1) or UBCx (5 or
20 µg ml–1) in the presence of (a) Q2 or (b)
CDC27-IP. (c,d) Quantitation of the (c) low
and (d) high mass conjugates formed in the
Q2 reactions shown in (a). 
attaching preformed ubiquitin chains that may exist in
vivo [37]. It is also possible that UBC4 and UBCx may be
somewhat redundant for cyclin B degradation, but could
have more independent functions in the degradation of
other substrates that are ubiquitinated by APC at
anaphase.
What is the mechanism of cyclin ubiquitination?
Cyclin ubiquitination reactions reconstituted with either
UBCx or UBC4 exhibited similar kinetics and were
equally APC- and D box-dependent, suggesting that
recognition of the cyclin substrate occurs through the
same mechanism in both cases. The MATa2 degradation
system in yeast also involves multiple E2s [23]. In this
system, four different ubiquitin-conjugating enzymes
promote the degradation of MATa2 through two differ-
ent ubiquitination pathways that recognize distinct
degradation signals.
It is presently unclear whether UBCx and UBC4 interact
with cyclin directly or whether substrate recognition is
exclusively mediated by APC. The latter possibility is
more likely for several reasons: UBC4 is known to partici-
pate in the ubiquitination of many different substrates
[23–26] and is therefore unlikely to confer substrate speci-
ficity directly. In other ubiquitination reactions, such as the
N-end rule pathway and p53 ubiquitination, it has also
been demonstrated that substrate recognition is mediated
by the E3 component, not by the E2 enzyme [38,39]. In
the case of p53 ubiquitination, it has been shown that ubiq-
uitin is transferred through a thioester cascade from E1 via
E2 to the E3 (E6-E6AP) [25,40]. Ubiquitin is then trans-
ferred from the E3 to the substrate in an E2-independent
reaction. Whether APC, UBCx and UBC4 ubiquitinate
cyclin B according to a similar mechanism is still unknown. 
The distinct properties of UBCx and UBC4 in the ubiqui-
tination of the same substrate suggest two possible mecha-
nisms and means for distinguishing them. If the
mechanism were similar to p53 ubiquitination, UBCx and
UBC4 would transfer ubiquitin to APC to form an
APC–ubiquitin thioester, which would then donate ubiq-
uitin to cyclin (Fig. 10a). In one view, where the cyclin
would dissociate from APC between each cycle of ubiqui-
tination, we would not expect there to be a difference in
the pattern of conjugates, because the nature of the E2s
would not influence the subsequent reaction. However, if
the cyclin remains bound as shown in Figure 10a, and the
ubiquitin transfer from UBCx or UBC4 to APC is rate
limiting, then the nature of the E2 could influence the
processivity of the reaction. It is also conceivable that
UBCx and UBC4 could transfer ubiquitin to different
sites on APC. Alternatively, the E2s could transfer ubi-
quitin directly to the substrate without the formation of a
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Figure 10
Hypothetical mechanisms of cyclin
ubiquitination. In model (a), ubiquitin is
transferred to cyclin via an E1-E2-E3 thioester
cascade. Because UBCx and UBC4 catalyze
the formation of cyclin–ubiquitin conjugates
with distinct patterns, this model can only be
valid if k3 is not rate limiting. In this case,
UBC4 would transfer ubiquitin to APC with a
higher rate than UBCx, allowing more cycles
of ubiquitin conjugation during the residence
time of the substrate on APC (k1 < k2). In
model (b), ubiquitin is transferred directly from
E2s to cyclin in a reaction mediated by APC.
In this case, no APC–ubiquitin thioester
intermediates would be formed and APC
would act as an ‘adaptor’ to bring E2s and
cyclin to close proximity. The difference in the
pattern of conjugates generated by UBCx and
UBC4 could therefore be the result of
different rates with which the E2s transfer
ubiquitin to cyclin (k1 < k2).
ubiquitin thioester on APC, but in a reaction mediated by
APC (Fig. 10b). In this model, the difference in the pro-
cessivity of cyclin ubiquitination catalyzed by UBCx and
UBC4 would reflect the different rates of ubiquitin trans-
fer to cyclin. UBC4 would transfer ubiquitin to cyclin with
a higher rate than UBCx, resulting in the assembly of
longer ubiquitin chains during the residence time of cyclin
bound to APC. Characterization of the subunits of APC
that are involved in E2 binding, substrate recognition, and
ubiquitin transfer will help resolve the mechanism of
cyclin ubiquitination.
Conclusions
We have purified and cloned UBCx, a novel ubiquitin-
conjugating enzyme involved in cyclin B ubiquitination in
Xenopus. In the presence of mitotic APC, UBCx and
UBC4 catalyze the rapid attachment of ubiquitin to cyclin.
Both ubiquitin-conjugating enzymes function through
similar mechanisms, requiring the anaphase-promoting
complex and the same recognition signal on cyclin.
However, UBCx and UBC4 generate cyclin-ubiquitin
conjugates with different patterns, suggesting that they
may play distinct roles in cyclin ubiquitination. 
Materials and methods
Protein purification and microsequencing
Interphase and mitotic Xenopus egg extracts and the corresponding
high speed supernatants were prepared as described previously [16].
All column chromatography was performed with an FPLC system (Phar-
macia) at 4 °C. For the purification of UBCx, each column fraction was
desalted with PD10 columns (Pharmacia), concentrated in Centriprep-
10 concentrators (Amicon), and tested for cyclin ubiquitination and
ubiquitin thioester-forming activities. Diluted S100 supernatant was
applied to a 50 ml Resource Q column (Pharmacia) equilibrated with
buffer Q-A (20 mM Tris-HCl pH 7.7, 100 mM KCl, 1 mM CaCl.2, 1 mM
MgCl.2, 1 mM DTT). The flowthrough (fraction Q1) was precipitated with
80 % ammonium sulfate. The precipitate was resuspended in buffer P-A
(20 mM Tris-HCl pH 7.7, 1.2 M ammonium sulfate, 1 mM DTT), loaded
on a phenyl-sepharose column (Pharmacia), and eluted with buffer P-B
(20 mM Tris-HCl pH 7.7, 1 mM DTT). The active fractions were
exchanged into buffer Q-A9 (20 mM Tris-HCl pH 9.0, 1 mM DTT),
applied to a 5 ml Hi-Trap Q column (Pharmacia), and eluted with buffer
Q-B9 (Q-A9 + 1 M KCl) with a 0–35 % gradient. The active fractions
were then separated on a 125 ml Superdex-75 column (Pharmacia)
equilibrated with Q-A. UBCx-containing fractions were separated on
15 % SDS-polyacrylamide gels, transferred to a PVDF membrane (Bio-
Rad), and stained with 0.1 % amidoblack in 10 % methanol and 2 %
acetic acid. The putative 21 kDa UBCx band was excised (about 2 µg of
protein), and processed for peptide sequencing at the Harvard Micro-
chemistry Facility. Briefly, the protein was digested with Lys-C, frag-
ments were separated by HPLC, and two peptides were sequenced by
automated Edman degradation. The final preparation of UBCx used for
sequencing was derived from a total of 220 ml of concentrated extract.
Cloning of human UBCx and Xenopus UBCx and UBC4
We searched the EST database at the NCBI with the sequence of
peptide A using the BLAST network service and found an open
reading frame encoded by three ESTs (R80990, R95056, T86566)
that matched the query peptide with 83 % identity. On the basis of
these EST sequences, we isolated a cDNA from a human testis
library using the GeneTrapper cloning system (GibcoBRL). A capture
oligonucleotide (5′-AAGACCTGAGGTATAAGCTCTCGC-3′) was
synthesized and 5′-biotinylated. A phagemid human testis cDNA
library (GibcoBRL) was converted to single-stranded (ss) DNA using
Gene II (phage F1 endonuclease) and E. coli Exonuclease III (ExoIII).
The biotinylated capture oligonucleotide was then annealed to the
ssDNA library and the hybridized DNA was isolated using strepta-
vidin-coated paramagnetic beads. The isolated ssDNA molecules
were converted into double-stranded (ds) DNA with the repair
enzyme and a repair primer (5′-CACAGTGAAGTTCCTCACGCC-
CTG-3′). The dsDNA clones were transformed into E. coli strain
DH10B (GibcoBRL) and plated. Colony PCR was used to identify
the desired clones. About 10 % of the clones obtained from this pro-
cedure were positive. One clone (H.s.UBCx-1) was sequenced on
both strands. 
For the cloning of Xenopus UBCx, two degenerate oligonucleotides
(5′-GGXACXGTXTAYGARGA-3′, 5′-GGRTGRAARCAXGGXGT-3′;
X = A/C/G/T; R = A/G; Y = C/T) were designed on the basis of the
two peptide sequences. They were used as PCR primers to assay 80
pools of a plasmid library containing cDNA inserts from Xenopus
embryos (stage 10–10.5) [28]. Each pool contained about 700 inde-
pendent clones. The two positive pools were subsequently divided
until a single clone was obtained, and one of these, X.l.UBCx-1, was
sequenced on both strands. 
The Xenopus UBC4 cDNA was isolated in a similar manner, using
degenerate oligonucleotides specific for UBC4. The upstream primer
was based on the sequence EYPSKPPKV and the downstream primer
based on the sequence PNPNSPA. The primer sequence were as
follows (I indicates inosine; R = A/G; S = G/C; W = A/T; Y = C/T):
Upstream primer: 5′-CCCTCTAGAGGATCCGAITAYCCITCIAARCCI-
CCIAARGT-3′; downstream primer: 5′-GGGAAGCTTGAATTCYT-
GIGCIGGISWRTTIGGRTTIGG-3′.
Preparation of recombinant ubiquitin-conjugating enzymes
The Xenopus UBCx cDNA was amplified by PCR with Pfu polymerase
(Stratagene), digested with NdeI and BamHI (NEB) and subcloned into
the pET11c vector (Novagen). The pET-UBCx plasmids were then
transformed into BL21(DE3) (Novagen) cells for protein expression.
The bacterial lysate was applied to a Hi-Trap Q column equilibrated
with Q-A. The flowthrough was precipitated with 80 % ammonium
sulfate. The precipitate was resuspended in buffer P-A and loaded on a
phenyl sepharose column. The UBCx fractions were concentrated and
fractionated with a Sephacryl S100 gel filtration column (Pharmacia).
The resulting UBCx protein was greater than 95 % pure, as judged by
silver-staining. The human UBCx gene was subcloned into the pET11c
vector and the recombinant protein was purified in a similar fashion.
The Xenopus UBC4 gene was also subcloned into pET11c and
expressed in BL21(DE3) cells. The resulting recombinant UBC4
protein was purified to greater than 80 % purity by cation exchange
chromatography using a Hi-Trap SP column (Pharmacia). 
Thioester and ubiquitination assays
E2-thioester assays and ubiquitination assays were performed as
described [16]. Methylated ubiquitin was prepared as previously
described [41].
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